永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06978 永泰生物-B

已收盘 12-19 16:08:04

2.880

+0.110

+3.97%

最高2.900	最低2.750	成交量428.51万
今开2.890	昨收2.770	日振幅5.42%
总市值17.80亿	流通市值17.80亿	总股本6.18亿
成交额1,221万	换手率0.69%	流通股本6.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":2.88,"timestamp":1766131684822,"preClose":2.77,"halted":0,"volume":4285123,"delay":0,"floatShares":618000000,"shares":618000000,"eps":-0.4017352591604093,"marketStatus":"已收盘","change":0.11,"latestTime":"12-19 16:08:04","open":2.89,"high":2.9,"low":2.75,"amount":12211149,"amplitude":0.054152,"askPrice":2.88,"askSize":123000,"bidPrice":2.75,"bidSize":68000,"shortable":0,"etf":0,"ttmEps":-0.48037485125471735,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766367000000},"marketStatusCode":5,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":2.77,"openAndCloseTimeList":[[1766107800000,1766116800000],[1766120400000,1766131200000]],"volumeRatio":2.685495,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978","defaultTab":"news","newsList":[{"id":"2592955166","title":"创新药、新能源车等全线拉升","url":"https://stock-news.laohu8.com/highlight/detail?id=2592955166","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592955166?lang=zh_cn&edition=full","pubTime":"2025-12-19 18:51","pubTimestamp":1766141516,"startTime":"0","endTime":"0","summary":"【导读】港股三大指数集体收涨12月19日，港股三大指数高开高走，截至收盘，恒生指数上涨0.75%，恒生科技指数上涨1.12%，恒生国企指数上涨0.68%。创新药、新能源汽车等涨幅靠前具体来看，当日权重科技股集体上涨，腾讯、快手、网易、美团、百度均涨超1%。板块方面，当日创新药概念股涨幅靠前，其中，映恩生物涨幅达9.29%，药明生物涨幅达4.4%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512193596898585.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512193596898585.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["161028","BK1161","159992","BK1574","06978","399417"],"gpt_icon":0},{"id":"2592415986","title":"创新药板块观察：沉寂后的“大招”，估值修复行情启动？","url":"https://stock-news.laohu8.com/highlight/detail?id=2592415986","media":"投资者研究中心","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592415986?lang=zh_cn&edition=full","pubTime":"2025-12-19 15:08","pubTimestamp":1766128104,"startTime":"0","endTime":"0","summary":"12月19日，A股创新药板块迎来久违的集体反弹。不过，也应清醒认识到，创新药板块本身具有高波动性，受研发进展、临床数据、政策节奏、市场竞争等多重因素影响，单日大涨并不等同于趋势性反转，更多应视为政策驱动下的估值修复启动信号。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219152804a6b5f938&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219152804a6b5f938&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1576","LU0052750758.USD","LU1046422090.SGD","LU0708995583.HKD","02359","LU2045819591.USD","LU2125910500.SGD","BK1161","03347","06978","LU2242644610.SGD","BK1141","LU0320764599.SGD","BK1583"],"gpt_icon":0},{"id":"2592131496","title":"招商证券：医药板块创新药产业链仍是主线 重点关注小核酸等技术方向","url":"https://stock-news.laohu8.com/highlight/detail?id=2592131496","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592131496?lang=zh_cn&edition=full","pubTime":"2025-12-19 10:17","pubTimestamp":1766110668,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招商证券发布研报称，2026年医药板块在创新出海持续兑现、医疗内需分化的产业趋势下，有望出现结构行情。创新药产业链仍是主线，除观察二代IO、减重、ADC板块的临床数据外，尤其关注小核酸技术方向的加速发展；同时关注CXO、上游、原料药中具备景气度与业绩兑现的公司。创新及药品产业链CXO：在2025年以来，外需CXO业绩逐步兑现，分子类型持续革新带来新的产业机会；内需CRO需求结构性改善，新签订单持续增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383501.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","BK0188","BK1515","BK1564","BK0010","BK1574","09939","600999","BK1147","BK0276","BK0012","BK0183","BK0028","06978","BK1161","06099","159938"],"gpt_icon":0},{"id":"2592902107","title":"九典制药：正在全面转型创新药研发，迅速布局创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2592902107","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592902107?lang=zh_cn&edition=full","pubTime":"2025-12-18 22:13","pubTimestamp":1766067180,"startTime":"0","endTime":"0","summary":"九典制药在机构调研时表示，公司目前正在全面转型创新药研发，采用“多个研发中心+多种药物形式+多种合作模式”策略迅速布局创新药。(本文来自第一财经)\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2025-12-18/doc-inhcfvmf2970774.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-12-18/doc-inhcfvmf2970774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","BK1574","BK0239","06978","300705","BK1161"],"gpt_icon":0},{"id":"2592418332","title":"科学与健康丨登上《自然》！中国降糖减重药有新成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2592418332","media":"新华网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592418332?lang=zh_cn&edition=full","pubTime":"2025-12-18 17:59","pubTimestamp":1766051953,"startTime":"0","endTime":"0","summary":"中国降糖减重药有新成果新华社记者徐鹏航、陈席元基于中国国产创新药，由中国科研人员牵头、针对糖尿病治疗的降糖减重研究取得亮眼成果，12月18日登上国际知名学术期刊《自然》。参与研究的国内代谢与内分泌领域多位专家表示，此次临床研究成果正是基于中国患者，研究结论能够真实反映中国患者的疾病特征和治疗需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218180213a45b0482&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218180213a45b0482&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1589","LU1969619763.USD","LU2097828631.EUR","HK0000165453.HKD","LU2097828714.EUR","LU2097828805.USD","LU2242644610.SGD","BK1574","LU0455707207.USD","LU2488822045.USD","BK1161","06978","LU0502904849.HKD","LU2097828557.USD","01801","LU2097828474.EUR","LU2328871848.SGD"],"gpt_icon":0},{"id":"2592201369","title":"奥布替尼SLE临床试验突破背后 诺诚健华单产品依赖隐忧｜创新药观察","url":"https://stock-news.laohu8.com/highlight/detail?id=2592201369","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592201369?lang=zh_cn&edition=full","pubTime":"2025-12-18 15:03","pubTimestamp":1766041380,"startTime":"0","endTime":"0","summary":"12月15日，生物医药公司诺诚健华宣布，其核心产品奥布替尼用于治疗系统性红斑狼疮（SLE）的IIb期临床研究达到主要终点，并已获国家药品监督管理局批准开展Ⅲ期临床试验。这一进展虽标志着该药在开拓自身免疫疾病这一巨大新市场的道路上迈出关键一步，但其通往成功商业化的道路仍布满不确定性，或将面临来自临床试验、市场竞争及公司战略的多重严峻挑战。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512183595356395.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512183595356395.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","09969","BK1161","688428","SLE","BK4077","BK0239","159992","06978"],"gpt_icon":0},{"id":"2592513924","title":"创新药概念逆市上扬 石药集团(01093)午后升幅扩至近6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592513924","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592513924?lang=zh_cn&edition=full","pubTime":"2025-12-18 13:21","pubTimestamp":1766035316,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念逆市上扬，石药集团 升5.98%，药明生物升1.97%，药明合联升1.56%，先声药业升1.51%，药明康德升1.28%。开源证券指出，当前纳入医保+商保的创新药大多处于未放量以及低基数阶段，随着医保支持创新药的政策红利持续释放，我们认为纳入双目录的创新药收入有望快速提升，患者有望持续受益，同时相关创新药企也随之迎来弹性增长。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/ZDQyZmM0MDNhYTRlOWFhOWE0NDBjZGFmOTc4ZmU3NDQzMjc2MzA4MTk4NA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZDQyZmM0MDNhYTRlOWFhOWE0NDBjZGFmOTc4ZmU3NDQzMjc2MzA4MTk4NA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971799","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0588546209.SGD","BK1574","LU0456827905.SGD","LU0348735423.USD","LU1242518931.SGD","BK1191","LU1794554557.SGD","BK1515","SG9999002463.SGD","IE00BZ08YS42.EUR","IE0008369823.USD","LU1328277881.USD","02269","BK1610","LU1242518857.USD","LU1688375341.USD","IE00B543WZ88.USD","LU0140636845.USD","IE00BZ08YT58.USD","01093","IE00BZ08YR35.GBP","06978","LU0856984785.SGD","IE00B031HY20.USD","LU0181495838.USD","02096","LU0501845795.SGD","02359","LU0315179316.USD","LU1226287875.USD","LU1226287792.SGD","LU1807302812.USD","LU1813983027.USD","SG9999002562.SGD","LU0039217434.USD","LU3063872942.SGD","LU0052750758.USD","BK1589","LU0348825331.USD","LU0051755006.USD","LU1046422090.SGD","LU1152091754.HKD","IE00B5MMRT66.SGD","02268","LU1008478684.HKD","LU0572944931.SGD","159992","LU0307460666.USD","LU0320764599.SGD","BK1583"],"gpt_icon":0},{"id":"2592901691","title":"刚刚直线拉升！美国传来大消息！创新药风险阶段性出清","url":"https://stock-news.laohu8.com/highlight/detail?id=2592901691","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592901691?lang=zh_cn&edition=full","pubTime":"2025-12-18 11:43","pubTimestamp":1766029380,"startTime":"0","endTime":"0","summary":"今早，A股和港股创新药皆由低位直线拉升，华人健康20%涨停，塞力医疗、重药控股涨停，新诺威、多瑞医药、新天药业、南新制药等表现强势。创新药大消息北京时间2025年12月18日凌晨，参议院官网显示，搭载修订版《生物安全法案》的美国2026财年国防授权法案以77票赞成，20票反对结果获得参议院通过，后续将送往白宫，由美国总统签署后立即生效。有券商研究机构认为，2025年法案进展阶段性落地，行业回归中长期增量逻辑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218120659a6b0bd42&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218120659a6b0bd42&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1589","LU0043850808.USD","LU1794554557.SGD","LU0588546209.SGD","LU0516422952.EUR","LU1880383366.USD","BK1576","LU0417516902.SGD","LU0516422366.SGD","LU2039709279.SGD","LU0417516738.SGD","LU0823426480.USD","BK1574","BK1521","LU0320764599.SGD","LU0856984785.SGD","LU0456827905.SGD","SG9999002562.SGD","LU0348825331.USD","LU0326950275.SGD","LU1242518857.USD","LU0051755006.USD","LU1242518931.SGD","LU0819121731.USD","LU0572944931.SGD","LU0307460666.USD","LU0516423091.SGD","BK1610","LU0516423174.USD","LU3063872942.SGD","BK1161","02269","LU0456846285.SGD","LU0039217434.USD","LU0052750758.USD","06978","SG9999002463.SGD","BK1141","LU0348735423.USD","LU0140636845.USD","LU0708995583.HKD","LU0516422440.USD","LU0823426308.USD","LU0359201612.USD","LU0327786744.USD","LU1688375341.USD","LU1720050803.USD","LU0979878070.USD","LU0181495838.USD","LU0359202008.SGD"],"gpt_icon":0},{"id":"2592490556","title":"医药行业周报：年末国产创新药出海交易密集落地 2026年向上趋势中价值回归可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2592490556","media":"交银国际","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592490556?lang=zh_cn&edition=full","pubTime":"2025-12-18 00:00","pubTimestamp":1765987200,"startTime":"0","endTime":"0","summary":"本周内资主要加仓龙头创新药企，包括恒瑞医药、荣昌生物和映恩生物；亦布局潜在受益于下游复苏的龙头CXO 企业，增持昭衍新药、晶泰控股和药明合联。投资启示：本周多项超10 亿美元的BD 交易相继落地，合作伙伴既有MNC也有中小型生物科技公司。临近年末，我们继续看好新BD 交易集中落地机会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218192135a45b4ef9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218192135a45b4ef9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","BK1161","BK1574","LU2543165471.USD","BK1191","LU0359201612.USD","LU0359201885.HKD","02192","LU0359202008.SGD","LU1023057109.AUD","06978"],"gpt_icon":0},{"id":"2592995279","title":"永泰生物-B12月17日主力净流入673.2万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2592995279","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592995279?lang=zh_cn&edition=full","pubTime":"2025-12-17 16:16","pubTimestamp":1765959368,"startTime":"0","endTime":"0","summary":"12月17日, 永泰生物-B股价涨0.71%，报收2.85元，成交金额766.0万元，换手率0.43%，振幅2.47%，量比2.35。永泰生物-B今日主力资金净流入673.2万元，上一交易日主力净流出0万元。该股近5个交易日下跌0.35%，主力资金累计净流入1256.8万元；近20日主力资金累计净流入1854.5万元，其中净流入天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217162337a4560611&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217162337a4560611&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","BK1161","BK1574"],"gpt_icon":0},{"id":"2592943229","title":"中国创新药领域已构成“黄金三角”，行业发展迎来强劲动能","url":"https://stock-news.laohu8.com/highlight/detail?id=2592943229","media":"制药网","labels":["economic"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592943229?lang=zh_cn&edition=full","pubTime":"2025-12-17 09:46","pubTimestamp":1765935968,"startTime":"0","endTime":"0","summary":"当前中国创新药产业正迎来历史性突破。而这一跨越的背后，业内指出，是研发投入做“加法”、审评审批流程做“减法”、市场空间做“乘法”构成的“黄金三角”正向循环，为创新药发展注入了强劲动能。此外，2025年至今，国内已批准上市的创新药达到69个，再创新高。其中，12月7日，国家医保局正式发布2025年国家医保目录和首版商保创新药目录，新增了114种药品纳入医保报销范围，包含50种1类创新药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217094734a4549957&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217094734a4549957&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201612.USD","BK1191","LU1023057109.AUD","BK1574","LU0359202008.SGD","LU2543165471.USD","BK1161","02615","06978","LU0359201885.HKD","01276"],"gpt_icon":0},{"id":"2591984365","title":"中国创新药崛起背后的“加减法”：为真创新提供真支持","url":"https://stock-news.laohu8.com/highlight/detail?id=2591984365","media":"三里河","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591984365?lang=zh_cn&edition=full","pubTime":"2025-12-16 20:38","pubTimestamp":1765888691,"startTime":"0","endTime":"0","summary":"2025年的最后一个月，外界期待已久的医保商保“双目录”对外公布。值得关注的是，新版国家医保目录里新增了111种5年内新上市药品，50种为1类新药，无论是比例还是数量，都创历年新高。这背后，医保基金正成为中国创新药产业发展的关键支撑之一，为“真创新”提供“真支持”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512163593227929.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","BK1574","159992","BK1161"],"gpt_icon":0},{"id":"2591498558","title":"利空突袭，5倍创新药牛股大幅杀跌，股价腰斩","url":"https://stock-news.laohu8.com/highlight/detail?id=2591498558","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591498558?lang=zh_cn&edition=full","pubTime":"2025-12-16 18:39","pubTimestamp":1765881540,"startTime":"0","endTime":"0","summary":"　　昔日5倍大牛股，连日遭遇疯狂抛售。　　12月15日，一品红的股价走势上演了戏剧性一幕：开盘即大幅下探，短短半小时内便触及20%跌停线，12月16日继续大幅下挫跌超10%，截至收盘报33.42元/股，市值缩水至150亿元左右，创近半年新低。　　该股从去年9月底到今年7月，涨幅超过500%，但随后一路走弱，股价较最高位已经腰斩。年初至今涨幅回落至100%内。　　就在12月15日晚，一品红还发布了利好公告，公司拟以集中竞价交易方式回购股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/s/2025-12-16/doc-inhaywrc3128345.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2025-12-16/doc-inhaywrc3128345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","06978","159992","BK1574"],"gpt_icon":0},{"id":"2591935320","title":"深度研究报告|创新药出海潮起：恒瑞医药、百济神州领航","url":"https://stock-news.laohu8.com/highlight/detail?id=2591935320","media":"药视声Medispace","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591935320?lang=zh_cn&edition=full","pubTime":"2025-12-16 13:21","pubTimestamp":1765862507,"startTime":"0","endTime":"0","summary":"▲ 定档2026年5月29-30日苏州！精益智造·链接全球：2026中国制药产业大会重磅官宣！●如需获取完整版报告，关注“药视声”并回复“出海”，即可获得！文章来源：东吴证券研究所","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216132749a6a809cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216132749a6a809cd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1303224171.USD","LU0307460666.USD","01276","BK1161","LU1023057109.AUD","LU2328871848.SGD","LU0359202008.SGD","BK1191","LU1251922891.USD","LU0359201612.USD","BK1583","LU0359201885.HKD","BK1588","LU0588546209.SGD","BK1500","06978","BK1574","LU2543165471.USD","LU1770034418.SGD","LU1969619763.USD","06160","LU1719994722.HKD"],"gpt_icon":0},{"id":"2591983074","title":"围绕2030年发展，多家国内外药企发布相关战略及愿景！","url":"https://stock-news.laohu8.com/highlight/detail?id=2591983074","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591983074?lang=zh_cn&edition=full","pubTime":"2025-12-16 13:11","pubTimestamp":1765861889,"startTime":"0","endTime":"0","summary":"2025年，有多家国内外药企围绕2030年发展，发布了相关战略或明确核心愿景，涵盖创新研发、商业化目标、全球化布局等多个维度。云顶新耀近日，云顶新耀发布2030年发展战略，系统规划了未来五年的发展路径。复星医药复星医药在2030年前设定了多项发展目标，主要聚焦于创新药研发、国际化战略、市场地位提升及业务结构优化等方面。在去年其提出过“中国2030战略”，当前该战略首期答卷已在第八届进博会上披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216131228a450e749&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216131228a450e749&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01952","PFE","BK1574","06978","BK1583"],"gpt_icon":0},{"id":"2591565672","title":"创新药概念再度走低 诺诚健华(09969.HK)跌超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591565672","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591565672?lang=zh_cn&edition=full","pubTime":"2025-12-16 11:21","pubTimestamp":1765855266,"startTime":"0","endTime":"0","summary":"每经AI快讯，创新药概念股再度走低，截至发稿，诺诚健华(09969.HK)跌5.09%，报12.86港元；石药集团(01093.HK)跌3.99%，报7.21港元；信达生物(01801.HK)跌3.36%，报79港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512163592831521.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512163592831521.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09969","BK0239","06978","BK1161","688428","BK1574","159992"],"gpt_icon":0},{"id":"2591608402","title":"【券商聚焦】海通国际：医药板块短期承压 长期看好创新药产业链","url":"https://stock-news.laohu8.com/highlight/detail?id=2591608402","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591608402?lang=zh_cn&edition=full","pubTime":"2025-12-16 09:43","pubTimestamp":1765849420,"startTime":"0","endTime":"0","summary":"金吾财讯|海通国际发布研报指，本周恒生医疗保健指数下跌2.3%，跑输恒生指数1.8个百分点，主要受南下资金年底季节性结账影响。2025年初至今，该指数累计涨幅达68.3%，大幅跑赢恒生指数38.8个百分点。子板块中CXO/科研服务表现最佳，医疗器械跌幅最大。长期来看，机构看好业绩确定性强的互联网医疗、CXO/科研服务龙头，以及具备海外授权合作能力的头部Biotech。风险提示包括临床进展不及预期、集采政策风险及宏观环境不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216095428a4503682&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216095428a4503682&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0051755006.USD","00241","LU0456827905.SGD","BK1574","06978","09939","06618","SGXZ62798434.SGD","BK1571","BK1591","BK1247","02269","SGXZ86797644.SGD","BK1515","BK1615","BK1589","BK1583","BK1161","86618","BK1142"],"gpt_icon":0},{"id":"2591671041","title":"信达证券：创新跨越从跟跑至领跑 行业整体估值处于历史平均偏低的水平","url":"https://stock-news.laohu8.com/highlight/detail?id=2591671041","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591671041?lang=zh_cn&edition=full","pubTime":"2025-12-16 09:10","pubTimestamp":1765847456,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，信达证券发布研报称，2025年前三季度生物医药板块各子板块业绩表现大幅分化，高基数及集采和反腐压力已基本消化，2025年行业营收及利润总额同比增速先抑后扬，其中创新药及CXO和生命科学上游的景气度已反转，行业的盈利能力止跌企稳；创新药受益于BD预期带动年初至7月份医药指数大涨，8月份至今震荡调整，行业整体估值处于历史平均偏低的水平。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216092008a4501020&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216092008a4501020&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1197","BK1161","00874","01858","06618","BK1521","06978","BK1191","01789","BK1515","BK1606"],"gpt_icon":0},{"id":"2591342678","title":"创新药保障“最后一公里”待解","url":"https://stock-news.laohu8.com/highlight/detail?id=2591342678","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591342678?lang=zh_cn&edition=full","pubTime":"2025-12-16 07:00","pubTimestamp":1765839600,"startTime":"0","endTime":"0","summary":"年末，国家医保局与人力资源社会保障部同步发布新版国家医保目录及首版《商保创新药目录》，标志着我国医疗保障体系正式迈入“基本医保+商业健康险”双轮驱动的新阶段。这一结构性调整，不仅关乎行业格局，更直接触及每一位患者对前沿治疗方式的期待与焦虑。以商保承接高值创新药支付，是构建多层次医疗保障体系的关键拼图，旨在让患者面对重疾时多一份选择。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-12-16/doc-inhaxvcp1674477.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-12-16/doc-inhaxvcp1674477.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","BK1161","BK1574","159992"],"gpt_icon":0},{"id":"2591627189","title":"【ETF动向】12月15日华宝恒生港股通创新药精选ETF基金跌3.32%，份额增加1.42亿份","url":"https://stock-news.laohu8.com/highlight/detail?id=2591627189","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591627189?lang=zh_cn&edition=full","pubTime":"2025-12-16 06:32","pubTimestamp":1765837925,"startTime":"0","endTime":"0","summary":"证券之星消息，12月15日，华宝恒生港股通创新药精选ETF基金（520880）跌3.32%，成交额2.97亿元。当日份额增加了1.42亿份，最新份额为41.48亿份，近20个交易日份额增加3.66亿份。当日资金净流出2322.67万元（资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的），最新资产净值计算值为21.65亿元。华宝恒生港股通创新药精选ETF基金跟踪标的为恒生港股通创新药精选指数，成立（2025-06-27）以来超额回报为-2.79%，近一个月超额回报为-0.09%，管理人为华宝基金公司，基金经理为丰晨成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600003764.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1161","06978","159992"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":-0.0142},{"period":"1month","weight":-0.115},{"period":"3month","weight":-0.4205},{"period":"6month","weight":-0.0977},{"period":"1year","weight":0.2149},{"period":"ytd","weight":0.2043}],"compareEarnings":[{"period":"1week","weight":-0.0013},{"period":"1month","weight":-0.0167},{"period":"3month","weight":-0.0394},{"period":"6month","weight":0.0836},{"period":"1year","weight":0.2836},{"period":"ytd","weight":0.2711}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化的投资控股公司。该公司的非转基因细胞产品管线包括EAL和6B11-OCIK注射液。该公司的嵌合抗原受体T（CAR-T）细胞产品管线包括CAR-T-19注射液、迪诺仑赛注射液和aT19注射液。该公司的T细胞受体工程化T细胞疗法（TCR-T）细胞产品管线包括YT003、YT008及YT007。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.065686},{"month":2,"riseRate":0.6,"avgChangeRate":0.206387},{"month":3,"riseRate":0.4,"avgChangeRate":-0.092735},{"month":4,"riseRate":0.2,"avgChangeRate":-0.078794},{"month":5,"riseRate":0.4,"avgChangeRate":-0.038349},{"month":6,"riseRate":0.8,"avgChangeRate":0.080731},{"month":7,"riseRate":0.2,"avgChangeRate":-0.000149},{"month":8,"riseRate":0.5,"avgChangeRate":0.012587},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.035807},{"month":10,"riseRate":0.5,"avgChangeRate":-0.057833},{"month":11,"riseRate":0.5,"avgChangeRate":0.001253},{"month":12,"riseRate":0.666667,"avgChangeRate":0.058868}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}